Non-peptide

ATX-304

Also known as

O-304 · O304 · OS-01 · ATX304 · ATX 304 · Amplifier Therapeutics ATX-304 · Cambrian ATX-304

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Oral research compound	ATX-304, also called O304, is a small molecule discussed for fat loss, glucose handling and training energy. Self-experiments use capsules or powder.
Energy-sensing pathway	Laboratory work describes keeping AMPK, a cellular energy sensor, activated. That mechanism does not promise better stamina.

Notes

An oral research drug, also called O304. ATX-304 is a small molecule discussed for fat loss, glucose handling and training energy. Capsules and powder appear in self-experiments; clinical formulations are separate. It is not an injectable peptide, a GLP-1 appetite drug, metformin or berberine, even though those names recur in comparisons.

AMPK helps cells respond to their energy supply. Laboratory work found O304 kept AMPK's activating chemical tag in place, without disabling the enzyme that removes it. This is more specific than saying it blocks a phosphatase. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients (Official context · Accessed 2026-09-30)

Uncoupling describes fuel use, not a promised benefit. The commercial guide also discusses mitochondria burning fuel while capturing less energy for cellular work. That is called uncoupling; it does not show that someone will have better stamina. ATX-304: naming and salt-form discussion (Community guide · Accessed 2026-09-30)

Source context — PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients: Animal/cell and small human study separated. Main text inspected; no supplemental terminal half-life table reviewed; steady state cannot establish four-day half-life.

Source context — ATX-304: naming and salt-form discussion: Commercial chemical supplier; guide cannot establish human effectiveness, comparative absorption or product purity. OS-01 ambiguity attributed to the guide, not independently verified from OneSkin.

What people notice

Steadier energy, or little change	One user described a gradual steady lift and easier cardio. Another noticed no cardio improvement; warmth, fidgetiness and nonresponse also appear.
Weight loss during dieting	One account claimed about 1.5 lb/week while dieting. The author's estimate of extra calories burned was not measured.
Recovery can feel worse	Roundtable speakers described poorer recovery, less muscle fullness or exhaustion, including ATX with SLU. One reported better progress after removing ATX.

Notes

Better energy is one experience, not the only one. ChocoFlan50 described a gradual, steady lift without heat or appetite change. TeaOk7705 reported faster loss with BAM15 co-use but no noticeable cardio improvement; an estimated 600-calorie expenditure increase was not measured. ATX-304 vs SLU-PP-332 vs BAM15 (Community discussion · Accessed 2026-09-30)

Cardio improvement and nonresponse coexist. ChocoFlan50 said their usual 35-minute limit became easier; TeaOk7705 noticed neither better nor worse cardio. Silent_Preference437 described better mood and motivation with caffeine and retatrutide also involved. These are different accounts, with different confounding. ATX-304 vs SLU-PP-332 vs BAM15 (Community discussion · Accessed 2026-09-30)

Gradual energy changes, without a dependable day. ChocoFlan50 described energy building over time rather than an immediate hit, but gave no exact onset. The older record also includes no change, warmth or fidgetiness; none establishes the expected first-day response. ATX-304 vs SLU-PP-332 vs BAM15 (Community discussion · Accessed 2026-09-30)

A weight-loss account with an uncertain explanation. otisw claimed about 1.5 lb/week while dieting, estimating a 200–300-calorie deficit and attributing the extra loss to ATX. That explanation is not a measured increase in calories burned. BAM-15, SLU-PP-332 or 915, ATX-304 (Personal report · Accessed 2026-09-30)

Less recovery can accompany the fat-loss enthusiasm. One roundtable speaker described poorer recovery and muscle fullness, with improved progress after removing ATX. Another remained exhausted with ATX plus SLU. Transcript dose exchanges were ambiguous. Anabolic Round Table: Steroids to Avoid, Permanent Damage, GH, GLP-1s & Why The Stack Matters (Personal report · Accessed 2026-09-30)

Source context — ATX-304 vs SLU-PP-332 vs BAM15: Anonymous unverified products, subjective outcomes, sequential or combined compounds. OP and OP's replies are one account; BAM15 heart-rate comment is not an ATX adverse report. Relative dates only displayed. TeaOk7705 prints ATX 100 am/100 pm without explicit units, so this is not adopted as a measured mg/day total.

Source context — BAM-15, SLU-PP-332 or 915, ATX-304: One self-account with estimated dietary deficit, not calorimetry; no verified compound identity or salt equivalence. SLU-specific later reports excluded from ATX evidence.

Source context — Anabolic Round Table: Steroids to Avoid, Permanent Damage, GH, GLP-1s & Why The Stack Matters: Transcript read, audio not checked. Speaker turns not consistently named and amounts ambiguously exchanged; no reliable frequency/route for each speaker. Bodybuilding/steroid and stack context. No transcript dosing reconstructed. Episode description contains peptide/clinic discount codes and coaching/supplement promotion.

Doses people talk about

100 mg account	One user reported 100 mg orally once daily with food. A different ATX/BAM15 account wrote '100' morning and evening without stating the unit.
200–350 mg accounts	Separate users described 200 mg/day or 200–350 mg/day split twice, the latter identifying free-acid material. These are individual reports.
400 mg daily ledger	One exposure ledger records two 200 mg oral administrations daily. The entry documents use rather than an efficacy result.

Notes

100 mg orally once daily with food. ChocoFlan50 reported this ATX amount separately from their BAM15 and SLU experiments. TeaOk7705 instead wrote ATX “100” morning and evening (unit unstated), with BAM15 co-use. ATX-304 vs SLU-PP-332 vs BAM15 (Community discussion · Accessed 2026-09-30)

200 mg/day and 200–350 mg/day are separate logs. Josh Large reported 200 mg daily. otisw reported 200–350 mg/day split twice, identifying free-acid material. These are accounts, not a recommended range. ATX-304 — Josh Large (Personal report · Accessed 2026-09-30) · BAM-15, SLU-PP-332 or 915, ATX-304 (Personal report · Accessed 2026-09-30)

400 mg/day as two 200 mg oral administrations. N=1 After 40 records this total from August 26, 2026; it is a personal exposure ledger, not an efficacy result. ATX-304 personal experiment ledger (Personal report · Accessed 2026-09-30)

Source context — ATX-304 — Josh Large: 27 comments listed but not accessible. Exercise and SLU co-use prevent isolating ATX or determining incidence.

Source context — ATX-304 personal experiment ledger: A personal active experiment with BAM15, SLU-PP-915, SANA, retatrutide and training; no final efficacy or tolerability result. Inventory is not extra dosing.

Half-life, onset & duration

Felt onset	One user described energy building gradually without an exact starting day.
Felt duration	The reports do not establish hours of benefit from one administration or a dependable after-stopping window.
Half-life	About four days is unverified X lore. A human report's day-14 stabilization of levels does not provide a numerical terminal half-life.

Notes

No reliable felt window or stopping clock. The reports do not establish hours of benefit from one administration. Multiweek weight logs answer a different question. Older claims of no peptide-like crash after stopping do not establish withdrawal behavior, clearance or when effects disappear.

About four days is unverified X lore. The retained X account uses this estimate to explain daily-versus-weekly arguments. Its measurement basis is unresolved. It cannot establish how long an unverified capsule lasts or validate weekly administration.

Clinical markers are different from felt energy. The 2018 human report described levels stabilizing around day 14, not a numerical terminal half-life. That is not an onset or weekly-dose calculation. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients (Official context · Accessed 2026-09-30)

Cycles people discuss

Observed courses	One account describes eight weeks; other experiments lasted a few weeks. These follow-up lengths do not establish a repeat calendar.
Daily and weekly experiments	Open-ended daily use, cost-limited months and weekly workarounds all appear. Exact weekly amounts and a validated break schedule are not established.

Notes

Eight weeks is one observed course. otisw described eight weeks of use; that is a follow-up length, not a proven cycle. Separate Reddit experiments lasted a few weeks each, without an exact ATX stop/repeat calendar. BAM-15, SLU-PP-332 or 915, ATX-304 (Personal report · Accessed 2026-09-30) · ATX-304 vs SLU-PP-332 vs BAM15 (Community discussion · Accessed 2026-09-30)

Daily, months-long and weekly experiments compete. Older discussion includes open-ended daily use, cost-limited months, continuous ATX alongside changing GLP amounts, and Nelly's weekly workaround. Exact weekly milligrams were not established in that record; none supplies a validated break or repeat schedule.

Stacks

GLP-related combinations	Semaglutide, tirzepatide and retatrutide appear in co-use reports. One 100 mg/day ATX-with-tirzepatide account claimed faster loss without noticed ATX side effects.
BAM15 and SLU	BAM15 accompanies one weight-loss report without better cardio. ATX/SLU reports include extra heat or exhaustion.
Other metabolic stacks	GH and apitegromab appear in older stack talk. Metformin, berberine and MOTS-c are often comparisons or replacements; some accounts do combine them.

Notes

More elaborate combinations make claims harder to assess. The retained discussion includes semaglutide, tirzepatide, retatrutide, GH and apitegromab; one 100 mg/day ATX-with-tirzepatide account claimed faster loss without noticed ATX sides. Lipid, liver-fat and fasting-insulin talk cannot isolate ATX within those combinations.

ATX 100 mg daily with tirz, n=1: Public 2026 log of ATX-304 100 mg with tirz, “no ATX sides,” faster fat-loss claim — one screenshot. [anecdote]

Sweat and heat deserve their own attention. Josh Large noticed more cardio sweat and extra heat with SLU. Co-use prevents attributing either to ATX alone. ATX-304 — Josh Large (Personal report · Accessed 2026-09-30)

Apitegromab: Tatem-linked discussion adds this antibody to ATX and a GLP drug. The proposed combination is not evidence of improved body composition or safety. [community]

GH: Nelly-linked historical discussion promotes GH with ATX, without a controlled combination outcome. [community]

Metformin and berberine: These appear as alternatives and as co-treatments. Shared metabolic interest does not establish equivalent effects or safe combined glucose responses. [community]

MOTS-c: Some accounts replace it with ATX; another combines them and attributes overnight symptoms to glucose changes. The proposed AMPK-overstimulation explanation remains unconfirmed. [community]

Source context — ATX-304 — Josh Large: 27 comments listed but not accessible. Exercise and SLU co-use prevent isolating ATX or determining incidence.

Watch for

Heat and recovery	Extra sweat, heat and poorer recovery appear, especially with other metabolic compounds. Co-use prevents assigning each symptom to ATX alone.
Overnight glucose concerns	One MOTS-c/O304 account described 4 a.m. wake-ups attributed to blood-sugar crashes, without confirming hypoglycemia. Glucose effects and interactions remain unresolved.
Form and long-term uncertainty	Trial tablets and research capsules are different evidence settings. OS-01 is an ambiguous product name; a label does not verify contents or long-term safety.

Notes

Stacking can change glucose and recovery. A retained MOTS-c plus O304 account describes 4 a.m. wake-ups attributed to blood-sugar crashes. This is not confirmed hypoglycemia. Metformin, berberine and GLP combinations add unresolved interactions; overnight glucose-monitoring discussion does not make a stack safe.

The name on a bottle leaves questions. A commercial Kimera guide flags OS-01 as an ambiguous name also used for a different skincare peptide. O304 and ATX-304 naming does not prove a particular product's contents or formulation. ATX-304: naming and salt-form discussion (Community guide · Accessed 2026-09-30)

Longer use remains uncertain. Small, short clinical studies and symptom-free personal logs cannot establish long-term safety or safety during pregnancy. Trial tablets and research capsules are not interchangeable. ATX is not a clot treatment or thyroid replacement. Cambrian Bio presents positive human translational data for ATX-304 (Official context · Accessed 2026-09-30)

Source context — ATX-304 — Josh Large: 27 comments listed but not accessible. Exercise and SLU co-use prevent isolating ATX or determining incidence.

Source context — Cambrian Bio presents positive human translational data for ATX-304: Sponsor press release about a small conference dataset; promotional interest, not a full independent peer-reviewed outcomes paper. Mirrors share this source family.

Full notes

ATX-304 is an investigational oral compound discussed for fat loss, metabolic health and training energy. Reports include steadier energy, little change, heat and poorer recovery. Product form and other compounds complicate interpretation.

What ATX-304 actually is

An oral research drug, also called O304. ATX-304 is a small molecule discussed for fat loss, glucose handling and training energy. Capsules and powder appear in self-experiments; clinical formulations are separate. It is not an injectable peptide, a GLP-1 appetite drug, metformin or berberine, even though those names recur in comparisons. Community
AMPK helps cells respond to their energy supply. Laboratory work found O304 kept AMPK's activating chemical tag in place, without disabling the enzyme that removes it. This is more specific than saying it blocks a phosphatase. Official context
Uncoupling describes fuel use, not a promised benefit. The commercial guide also discusses mitochondria burning fuel while capturing less energy for cellular work. That is called uncoupling; it does not show that someone will have better stamina. Community guide
The name on a bottle leaves questions. A commercial Kimera guide flags OS-01 as an ambiguous name also used for a different skincare peptide. O304 and ATX-304 naming does not prove a particular product's contents or formulation. Community guide

What people hope to gain

Fat loss without relying only on appetite suppression. The attraction is extra fuel use and metabolic improvement. Community pitches also promise easier cardio and lean-mass preservation; those promises exceed what personal reports can show. Some switch from MOTS-c or SS-31 after feeling little from the peptides. Community Community
Better energy is one experience, not the only one. ChocoFlan50 described a gradual, steady lift without heat or appetite change. TeaOk7705 reported faster loss with BAM15 co-use but no noticeable cardio improvement; an estimated 600-calorie expenditure increase was not measured. Reddit
A weight-loss account with an uncertain explanation. otisw claimed about 1.5 lb/week while dieting, estimating a 200–300-calorie deficit and attributing the extra loss to ATX. That explanation is not a measured increase in calories burned. Personal report

Doses people discuss

100 mg orally once daily with food. ChocoFlan50 reported this ATX amount separately from their BAM15 and SLU experiments. TeaOk7705 instead wrote ATX “100” morning and evening (unit unstated), with BAM15 co-use. Reddit
200 mg/day and 200–350 mg/day are separate logs. Josh Large reported 200 mg daily. otisw reported 200–350 mg/day split twice, identifying free-acid material. These are accounts, not a recommended range. Personal report Personal report
400 mg/day as two 200 mg oral administrations. N=1 After 40 records this total from August 26, 2026; it is a personal exposure ledger, not an efficacy result. Personal report
150 mg+ daily is a preserved influencer claim. BiohackerJake-linked discussion made cost part of that claim. Lower 100 mg accounts include limited added benefit. These are not escalation steps, metformin-equivalent grams or MOTS-c-equivalent injectable milligrams. Community Community

Half-life: what circulates

About four days is unverified X lore. The retained X account uses this estimate to explain daily-versus-weekly arguments. Its measurement basis is unresolved. It cannot establish how long an unverified capsule lasts or validate weekly administration. Community

Onset: what people notice

Gradual energy changes, without a dependable day. ChocoFlan50 described energy building over time rather than an immediate hit, but gave no exact onset. The older record also includes no change, warmth or fidgetiness; none establishes the expected first-day response. Reddit Community

Duration after a dose

No reliable felt window or stopping clock. The reports do not establish hours of benefit from one administration. Multiweek weight logs answer a different question. Older claims of no peptide-like crash after stopping do not establish withdrawal behavior, clearance or when effects disappear. Community

Courses and repeat-use patterns

Eight weeks is one observed course. otisw described eight weeks of use; that is a follow-up length, not a proven cycle. Separate Reddit experiments lasted a few weeks each, without an exact ATX stop/repeat calendar. Personal report Reddit
Daily, months-long and weekly experiments compete. Older discussion includes open-ended daily use, cost-limited months, continuous ATX alongside changing GLP amounts, and Nelly's weekly workaround. Exact weekly milligrams were not established in that record; none supplies a validated break or repeat schedule. Community

What can complicate the experiment

Sweat and heat deserve their own attention. Josh Large noticed more cardio sweat and extra heat with SLU. Co-use prevents attributing either to ATX alone. Personal report
Stacking can change glucose and recovery. A retained MOTS-c plus O304 account describes 4 a.m. wake-ups attributed to blood-sugar crashes. This is not confirmed hypoglycemia. Metformin, berberine and GLP combinations add unresolved interactions; overnight glucose-monitoring discussion does not make a stack safe. Community
Longer use remains uncertain. Small, short clinical studies and symptom-free personal logs cannot establish long-term safety or safety during pregnancy. Trial tablets and research capsules are not interchangeable. ATX is not a clot treatment or thyroid replacement. Community Official context

What the clinical and animal evidence adds

Clinical markers are different from felt energy. The 2018 human report described levels stabilizing around day 14, not a numerical terminal half-life. That is not an onset or weekly-dose calculation. Official context
A small sponsor-reported human signal. The sponsor's June 18, 2026 announcement described a randomized, placebo-controlled study enrolling 23 adults with obesity/prediabetes; participants received ATX-304 400 mg once daily or placebo for eight weeks. It reported liver and visceral fat, triglyceride and resting-metabolism changes but little weight loss. These clinical results do not validate self-experiment products or athletic outcomes. REWIRE studies were planned in that announcement. Official context
The semaglutide combination story began in mice. The sponsor's ENDO announcement covers mice, including semaglutide withdrawal. It cannot establish muscle preservation or prevention of rebound weight gain in people. Animal context

What the accounts add

Cardio improvement and nonresponse coexist. ChocoFlan50 said their usual 35-minute limit became easier; TeaOk7705 noticed neither better nor worse cardio. Silent_Preference437 described better mood and motivation with caffeine and retatrutide also involved. These are different accounts, with different confounding. Reddit
Less recovery can accompany the fat-loss enthusiasm. One roundtable speaker described poorer recovery and muscle fullness, with improved progress after removing ATX. Another remained exhausted with ATX plus SLU. Transcript dose exchanges were ambiguous. Personal report
Peptide comparisons are about expectations. Older accounts contrast loved-ATX training impressions with little felt MOTS-c benefit and dismiss ATX as expensive metformin. Morning use, walks and fasted cardio recur, while Jake-linked lore separates metformin from workouts. None establishes required movement or optimal timing. Community Community
More elaborate combinations make claims harder to assess. The retained discussion includes semaglutide, tirzepatide, retatrutide, GH and apitegromab; one 100 mg/day ATX-with-tirzepatide account claimed faster loss without noticed ATX sides. Lipid, liver-fat and fasting-insulin talk cannot isolate ATX within those combinations. Community
Cost and identity influence the discussion. Older notes favor metformin when ATX costs too much. Dry-powder storage shorthand does not verify stability or purity, and peptide-compounding debates do not establish ATX's status. Community